TY - JOUR T1 - Alcohol Consumption is Associated with Poor Prognosis in Obese Patients with COVID-19: a Mendelian Randomization Study using UK Biobank JF - medRxiv DO - 10.1101/2020.11.25.20238915 SP - 2020.11.25.20238915 AU - Xiude Fan AU - Zhengwen Liu AU - Kyle L Poulsen AU - Xiaoqin Wu AU - Tatsunori Miyata AU - Srinivasan Dasarathy AU - Daniel M. Rotroff AU - Laura E. Nagy Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/30/2020.11.25.20238915.abstract N2 - Background Acute and chronic alcohol abuse have adverse impacts on both the innate and adaptive immune response, which may result in reduced resistance to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and promote the progression of coronavirus disease 2019 (COVID-19). However, there are no large population-based data evaluating potential causal associations between alcohol consumption and COVID-19.Method We conducted a Mendelian randomization study using data from UK Biobank to explore the association between alcohol consumption and risk of SARS-CoV-2 infection and serious clinical outcomes in patients with COVID-19. A total of 12,937 participants aged 50-83 who tested for SARS-CoV-2 between 16 March to 27 July 2020 (12.1% tested positive) were included in the analysis. The exposure factor was alcohol consumption. Main outcomes were SARS-CoV-2 positivity and death in COVID-19 patients. We generated weighted and unweighted allele scores using three genetic variants (rs1229984, rs1260326, and rs13107325) and applied the allele scores as the instrumental variables to assess the effect of alcohol consumption on outcomes. Analyses were conducted separately for white participates with and without obesity.Results Of the 12,937 participants, 4,496 were never or infrequent drinkers and 8,441 were frequent drinkers. (including 1,156 light drinkers, 3,795 moderate drinkers, and 3,490 heavy drinkers). Both logistic regression and Mendelian randomization analyses found no evidence that alcohol consumption was associated with risk of SARS-CoV-2 infection in participants either with (OR=0.963, 95%CI 0.800-1.159; q =1.000) or without obesity (OR=0.891, 95%CI 0.755-1.053; q =.319). However, frequent drinking (HR=1.565, 95%CI 1.012-2.419; q =.079), especially heavy drinking (HR=2.071, 95%CI 1.235-3.472; q =.054), was associated with higher risk of death in patients with obesity and COVID-19, but not in patients without obesity. Notably, the risk of death in frequent drinkers with obesity increased slightly with the average amount of alcohol consumed weekly (HR=1.480, 95%CI 1.059-2.069; q =.099).Conclusions Our findings suggested alcohol consumption may had adverse effects on the progression of COVID-19 in white participants with obesity, but was not associate with susceptibility to SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by NIH grants: 3R01AA027456-02S1, P50AA024333, U01AA021890 and U01AA026938 (LEN); RO1GM119174, R21AR71046, UO1DK061732, RO1DK113196 and the Mikati foundation grant (SD); KL2TR002547 (DMR); K99AA026648 (KLP). XF was supported by a fellowship from the China Scholarship Council (File:201806280215) and TM was supported by a JSPS Overseas Research Fellowship 201960331.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank has obtained Research Tissue Bank (RTB) approval from its ethics committee and this study was also approved by the Institutional Review Boards of the Cleveland Clinic (IRB number:19582).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study used data from the UK Biobank (application number 59473). For details please contact access@ukbiobank.ac.uk. All other data are contained in the article and its supplementary information or available upon reasonable request. https://www.ukbiobank.ac.uk/ AbbreviationCOVID-19coronavirus disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus-2HRhazard ratioORodds ratioCIconfidence intervalNnumber of participantsADH1Balcohol dehydrogenase 1BBMIbody mass indexGERDgastroesophageal reflux diseaseCOPDchronic obstructive pulmonary diseaseAIDSacquired immunodeficiency syndromeICUintensive care unitARDSacute respiratory distress syndromeRSVrespiratory syncytial virusFDRfalse discovery rateSNPsingle nucleotide polymorphismPSMpropensity score matchingRAFrisk allele frequencyGERAGenetic Epidemiology Research in Adult Health and AgingADH1Balcohol dehydrogenase 1BGCKRglucokinase regulatorSLC39A8solute carrier family 39 member 8 ER -